sub:provenance {
beldoc: dce:description "Approximately 61,000 statements." ;
dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved." ;
dce:title "BEL Framework Large Corpus Document" ;
pav:authoredBy sub:_5 ;
pav:version "20131211" .
sub:_4 prov:value "Treatment of cells with GPCR agonists such as endothelin- 1 (ET-1), thrombin, bombesin, and lysophosphatidic acid (LPA) transactivates ErbB1 (reviewed by Zwick et al. [48]). Mechanistically, the process involves rapid stimulation of metalloproteinases followed by cleavage of an ErbB1 ligand precursor, e.g., pro-HB-EGF [49], whose binding activates ErbB1 and downstream signaling pathways" ;
prov:wasQuotedFrom pubmed:12648469 .
sub:_5 rdfs:label "Selventa" .
sub:assertion prov:hadPrimarySource pubmed:12648469 ;
prov:wasDerivedFrom beldoc: ,
sub:_4 .
}